

Treatment of high risk and oligo-metastatic prostate cancer

Poster Session 02

Friday, 24 March
09:00 - 10:30

Location: Room Amsterdam, North Hall (Level 1)

Chairs: B.J. Challacombe, London (GB)
S. Egawa, Tokyo (JP)
R.J. Karnes, Rochester (US)

Aims and objectives of this session

The aim of this session is to evaluate outcomes of treatments in high risk and oligo-metastatic prostate cancer

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.

- 17 **Attempted nerve sparing in high risk prostate cancer: Does it have an impact on oncological and functional outcomes? A retrospective long-term single center study**
By: [Furrer M.A.](#)¹, Gross T.¹, Nguyen D.P.¹, Boxler S.¹, Genitsch V.², Burkhard F.¹, Thalmann G.¹
Institutes:¹University Hospital Bern, Dept. of Urology, Bern, Switzerland, ²University Hospital Bern, Institute of Pathology, Bern, Switzerland
- 18 **Impact of preoperative risk on metastatic progression and cancer specific death in patients with adverse pathology at radical prostatectomy**
By: [Boehm K.](#)¹, Leyh-Bannurah S-R.², Rosenbaum C.², Budäus L.³, Graefen M.³, Haferkamp A.¹, Tilki D.³
Institutes:¹University Medical Center, Johannes Gutenberg University, Dept. of Urology and Pediatric Urology, Mainz, Germany, ²University Medical Center, Dept. of Urology, Hamburg, Germany, ³University Medical Center, Martini-Clinic, Hamburg, Germany
- 19 **Low rate of positive surgical margins are not associated with improved biochemical recurrence in high-risk prostate cancer patients**
By: Srougi V.¹, Sanchez-Salas R.¹, Secin F.², Baghdadi M.¹, Nunes-Silva I.¹, [Garcia-Barreras S.](#)¹, Rembeyo G.¹, Rozet F.¹, Galiano M.¹, Barret E.¹, Cathelineau X.¹
Institutes:¹Institut Montsouris, Dept. of Urology, Paris, France, ²CEMIC and San Lazaro Foundation, Dept. of Urology, Buenos Aires, Argentina
- 20 **Association between type 2 diabetes and curative treatment in men with intermediate and high risk localised prostate cancer**
By: [Crawley D.](#)¹, Garmo H.¹, Rudman S.², Stattin P.³, Zethelius B.⁴, Holmberg L.¹, Adolfsson J.⁴, Van Hemelrijck M.¹
Institutes:¹King's College London, Dept. of Cancer Epidemiology, London, United Kingdom, ²Guy's and St Thomas NHS Foundation Trust, Dept. of Medical Oncology, London, United Kingdom, ³Uppsala University, Dept. of Surgical Sciences, Uppsala, Sweden, ⁴Karolinska Institute, Dept. of Clinical Science, Intervention and Technology, Stockholm, Sweden
- 21 **Improved recurrence-free survival in locally advanced prostate cancer after robot-assisted radical prostatectomy with 3D-cancer mapping constructed by MRI/US fusion biopsy**
By: [Kamoi K.](#), Okihara K., Hongo F., Naitoh Y., Iwata A., Kanazawa M., Ushijima S., Ukimura O.
Institutes:Kyoto Prefectural University of Medicine, Dept. of Urology, Kyoto, Japan
- 22 **Assessing the 20-year outcomes of radical prostatectomy for high risk prostate cancer: Results from a large, multi-institutional series**
By: [Bianchi M.](#)¹, Colicchia M.³, Gandaglia G.², Munegato S.⁴, Fossati N.², Bandini M.², Stabile A.²,

Dell'Oglio P.², Suardi N.², Gontero P.⁴, Karnes J.³, Joniau S.⁵, Spahn M.⁶, Montorsi F.², Briganti A.²
Institutes:¹Magna Graecia University, Dept. of Urology, Catanzaro, Italy, ²Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴Molinette Hospital, Dept. of Urology, Turin, Italy, ⁵University Hospitals Leuven, Dept. of Urology, Leuven, Belgium, ⁶University Hospital of Bern, Dept. of Urology, Bern, Switzerland

- 23 **Oncological and functional outcomes after RP for high or very high-risk prostate cancer – European validation of the current NCCN guideline**
By: Pompe R.S.¹, Gild P.², Chun F.², Salomon G.¹, Leyh-Bannurah S-R.¹, Huland H.¹, Graefen M.¹, Karakiewicz P.³, Tilki D.¹
Institutes:¹Universitätsklinikum Hamburg-Eppendorf, Martini Clinic and Dept. of Urology, Hamburg, Germany, ²Universitätsklinikum Hamburg-Eppendorf, Dept. of Urology, Hamburg, Germany, ³University of Montreal Health Center, Cancer Prognostics and Health Outcomes Unit, Montreal, Canada
- 24 **Freedom from androgen deprivation and radiotherapy therapy after upfront minimally invasive surgery for high-risk prostate cancer**
By: Servián Vives P., Patel A., Winkler M.
Institutes:Imperial College Nhs Trust, Dept. of Urology, London, United Kingdom
- 25 **Survival associated with radical prostatectomy versus radiotherapy for high-risk prostate cancer: A contemporary, nationwide observational analysis**
By: Jindal T., Dalela D., Karabon P., Vetterlein M., Seisen T., Sood A., Trinh Q-D., Jeong W., Menon M., Abdollah F.
Institutes:Henry Ford Hospital, Dept. of Urology, Detroit, United States of America
- 26 **Impact of additional radiation and/or androgen deprivation therapy on functional outcomes after radical prostatectomy**
By: Tennstedt P.¹, Adam M.², Tilki D.¹, Steuber T.¹, Haese A.¹, Salomon G.¹, Petersen C.³, Huland H.¹, Graefen M.¹, Huber W.⁴, Schlomm T.¹
Institutes:¹University Medical Center Eppendorf, Martini-Klinik, Hamburg, Germany, ²University of Tübingen, Dept. of Urology, Tübingen, Germany, ³University Medical Center Eppendorf, Dept. of Radiooncology, Hamburg, Germany, ⁴European Molecular Biology Laboratory (EMBL), Genome Biology Unit, Hamburg, Germany
- 27 **Extended pelvic lymph node dissection for intermediate-high risk prostate cancer: Frequency and distribution of nodal metastases**
By: Roscigno M.¹, Nicolai M.¹, Naspro R.¹, Pellucchi F.¹, Cornaghi L.B.¹, Angiolilli D.¹, Chinaglia D.², Da Pozzo L.F.¹
Institutes:¹ASST Papa Giovanni XXIII, Dept. of Urology, Bergamo, Italy, ²ASST Papa Giovanni XXIII, Dept. of Pathology, Bergamo, Italy
- 28 **Predictors of early cancer specific and other cause mortality in high risk prostate cancer patients after radical prostatectomy: Results from a large, multi-institutional analysis**
By: Bianchi M.¹, Gandaglia G.¹, Fossati N.¹, Dell'Oglio P.¹, Joniau S.², Colicchia M.³, Munegato S.⁴, Bandini M.⁵, Spahn M.⁶, Scattoni V.⁵, Gontero P.⁴, Karnes J.³, Montorsi F.⁵, Briganti A.⁵
Institutes:¹Vita-Salute University San Raffaele; Magna Graecia University, Dept. of Urology, Milan, Italy, ²University Hospital of Leuven, Dept. of Urology, Leuven, Belgium, ³Mayo Clinic, Dept. of Urology, Rochester, United States of America, ⁴University of Turin, Dept. of Urology, Turin, Italy, ⁵Vita-Salute University San Raffaele, Dept. of Urology, Milan, Italy, ⁶University Hospital of Bern, Dept. of Urology, Bern, Switzerland
- 29 **Cytoreductive radical prostatectomy (cRP) is feasible in men with hormone-naive, metastatic prostate cancer (mPCA)**
By: Heidenreich A.¹, Briganti A.², Karnes J.³, Fossati N.², Gandaglia G.², Montorsi F.², Suardi N.², Colicchia M.³, Shariat S.⁴, Pfister D.¹
Institutes:¹Uniklinik Köln, Dept. of Urology, Cologne, Germany, ²Vita Salute San Raffaele University, Urological Research Institute, Milan, Italy, ³Mayo Clinic, Dept. of Urology, Rochester, United States

of America, ⁴Universitätsklinik Wien, Dept. of Urology, Vienna, Austria

30

Robot assisted radical prostatectomy in patients with oligometastatic prostate cancer

By: Jang W.S.¹, Heo J.E.¹, Oh K.T.¹, Kim M.S.¹, Kang D.H.¹, Jeong W.S.¹, Ham W.S.¹, Kim Y.S.², Choi J.R.³, Choi Y.D.¹

Institutes:¹Yonsei University College of Medicine, Dept. of Urology and Urological Science Institute, Seoul, South Korea, ²National Health Insurance Corporation Ilsan Hospital, Dept. of Urology and Urological Science Institute, Goyang, South Korea, ³Inje University College of Medicine, Dept. of Urology and Urological Science Institute, Gimhae, South Korea

31

Observation of preliminary clinical effect and analysis of perioperative complications of radical prostatectomy for patients with oligo-metastatic prostate cancer

By: Li G., Dai B., Ye D.

Institutes:Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China